Platform specialist Intrexon ($XON) has teamed up with Johnson & Johnson's ($JNJ) Janssen for a research collaboration to use its oral delivery system in therapies designed to treat Type 2 diabetes, obesity or metabolic disorders. The terms of the deal remain undisclosed.
Intrexon touts its ActoBiotics platform as one that can take on multiple aspects of Type 2 diabetes in a single pill and maintain glycemic control in the long term.
The pill delivers proteins and peptides to the oral and gastrointestinal tract using food-grade microbes called Lactococcus lactis engineered to contain the ActoBiotics drugs.
"I am very pleased we are partnering with Janssen to address Type 2 diabetes and related conditions," Intrexon Senior Vice President Samuel Broder said in a statement. "Through the use of Intrexon's proprietary ActoBiotics platform, we believe this collaboration will make a significant contribution to this substantial global health issue. The breadth of opportunity to treat an array of diseases with our versatile ActoBiotics technology continues to expand."
- here's the release